The Company has granted the underwriters an option, exercisable within 45 days from the closing date of the Offering, to purchase up to an additional 300,000 Ordinary Shares at the initial ...
Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative ...